Page 27 - Read Online

Table 1: Demographics, treatment and prognosis of the patients in China
Patient Sex Age Teratoma Surgery Glucocorticoids IVIg Serum Rituximab Anti‑ Prognosis Author
exchange virus
1 Female 13 No N/A Yes Yes - - - Completely Hu et al. [24]
normal
2 Female 13 No N/A Yes Yes - - Yes Completely
normal
3 Female 25 Yes Yes Yes Yes - - Yes Completely
normal
4 Female 19 Yes Yes - - - - - Self-maintenance Chen et al. [25]
5 Female 35 Yes Yes - Yes - - - Near Chen et al. [26]
self-maintenance
6 Female 25 No N/A Yes No - - Yes Obviously Song and Liu [27]
improved
7 Female 22 Yes Yes No Yes - - No Obviously
improved
8 Male 18 No N/A Yes No - - Yes Obviously
improved
9 Male 15 No N/A Yes No - - Yes Obviously
improved
10 Female 30 No N/A Yes Yes Yes - Yes Unfavorable
11 Female 18 No N/A Yes No - - Yes Obviously
improved
12 Female 26 Yes Yes Yes Yes - - Yes Death
13 Female 16 No N/A No Yes - - Yes Self-maintenance Xu et al. [28]
14 Male 12 No N/A Yes Yes - Yes - Favorable and Lu et al. [29]
no recurrence
15 Male 23 No N/A Yes Yes - - - Recurrence, but
improved after
IVIg again
16 Female 22 No N/A Yes Yes - - - Continuous
stupor-like state
17 Female 22 Yes Yes - Yes - - - Favorable and
no recurrence
18 Female 26 Yes Yes - Yes - - - Favorable and
no recurrence
19 Female 28 Yes Yes - Yes - - - Favorable and
no recurrence
20 Female 17 No N/A No Yes - - - Favorable and Wei et al. [30]
no recurrence
21 Female 24 Yes No Yes Yes - - - Favorable and Wu et al. [31]
no recurrence
22 Female 30 Yes Yes Yes Yes - - - Favorable and Peng et al. [32]
no recurrence
23 Female 6 No N/A - Yes - Yes - Favorable and Wang et al. [33]
no recurrence
24 Male 9 No N/A - Yes Yes - - Favorable and
no recurrence
25 Male 15 No N/A - Yes - - - Favorable and
no recurrence
26 Female 11 No N/A - Yes - - - Favorable and
no recurrence
27 Male 8 No N/A - Yes - - - Favorable and
no recurrence
28 Female 7 No N/A - Yes - - - Favorable and
no recurrence
29 Female 7 No N/A Yes Yes - - - Favorable and
no recurrence
30 Male 9 No N/A - Yes - - - Favorable and Zhang et al. [34]
no recurrence
31 Female 17 Yes Yes - Yes - - - Favorable and Shang et al. [35]
no recurrence
32 Female 17 Yes Yes Yes Yes - - - Favorable and Xu et al. [36]
no recurrence
33 Female 45 No N/A - Yes - - - Favorable and Our case
no recurrence
Contd...

20 Neuroimmunol Neuroinflammation | Volume 1 | Issue 1 | June 2014